The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated massive returns, the end of its patent opened the avenue to generic alternatives, https://social-lyft.com/story11740222/sildenafil-and-the-pharmaceutical-industry-a-precarious-bet